[144] Vir Biotechnology, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Vir Biotechnology, Inc. (VIR) shows a proposed sale of 66,000 common shares through Morgan Stanley Smith Barney with an aggregate market value of $376,860.00, targeting an approximate sale date of 10/01/2025 on NASDAQ. The shares were originally acquired as pre-IPO stock from the issuer on 01/17/2017. The filer has completed prior Rule 10b5-1 plan sales of 22,000 shares on 09/02/2025 for $109,810.80 and 22,000 shares on 08/01/2025 for $109,698.60. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information and references a trading plan date field if relying on Rule 10b5-1.

Positive

• Transaction details are fully disclosed including acquisition date, nature (pre-IPO), broker, and aggregate market value
• Prior 10b5-1 sales are reported for August and September 2025, indicating planned, orderly dispositions

Negative

• No information provided on whether the current sale is being made under an active 10b5-1 plan (the plan adoption date field is blank)
• Filing omits the filer CIK and contact details (fields shown but not populated), limiting traceability

Insights

Securities Analyst

TL;DR: Insider plans routine sale of vested pre-IPO shares via broker under Rule 144/10b5-1; recent 10b5-1 sales occurred in August and September.

The filing documents a non-derivative sale of 66,000 common shares by an insider who acquired the shares pre-IPO on 01/17/2017. The use of Morgan Stanley Smith Barney as broker and prior 10b5-1 plan sales of 22,000 shares in August and September 2025 suggest these are orderly, planned dispositions rather than opportunistic trades. The aggregate market value reported is $376,860, which is modest relative to total outstanding shares of 138,916,426 and therefore unlikely to materially affect market liquidity or company capitalization by itself. The filer affirms no undisclosed material adverse information.

Corporate Governance Expert

TL;DR: Filing appears to follow compliance norms for insider sales; includes required representations and references Rule 10b5-1 activity.

The Form 144 records acquisition details, original issuer source, and two recent 10b5-1 plan sales, indicating procedural compliance with securities resale rules. Disclosure that the shares were pre-IPO and acquired from the issuer satisfies provenance requirements. The statement asserting no knowledge of undisclosed material adverse information is standard and necessary for Rule 144 reliance. There is no indication in the filing of any unusual payment arrangements or contingent consideration.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	66000	376860.00	138916426	10/01/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/17/2017	Pre-IPO Shares	Issuer			66000	01/17/2017	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for VICKI LEE SATO 1800 Owens Street Suite 900 San Francisco CA 94158	Common	09/02/2025	22000	109810.80
10b5-1 Sales for VICKI LEE SATO 1800 Owens Street Suite 900 San Francisco CA 94158	Common	08/01/2025	22000	109698.60

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares does the Form 144 for VIR report?

The filing reports a proposed sale of 66,000 common shares of Vir Biotechnology with aggregate market value of $376,860.00.

When were the shares being sold originally acquired?

The shares were acquired as pre-IPO shares from the issuer on 01/17/2017.

Who is the broker handling the proposed sale?

The broker listed is Morgan Stanley Smith Barney LLC Executive Financial Services located at 1 New York Plaza, New York, NY.

Did the filer sell any VIR shares recently?

Yes. The filing discloses 10b5-1 sales of 22,000 shares on 08/01/2025 for $109,698.60 and 22,000 shares on 09/02/2025 for $109,810.80.

On what exchange is the sale expected to occur?

The approximate sale is expected to occur on NASDAQ with an approximate date of 10/01/2025.